BIO-Europe Spring 2019: Adrenomed’s Hein On Sepsis And Beyond
Adrenomed’s chief business officer Frauke Hein explained to Mike Ward how the company has moved from establishing a diagnostic marker for septic shock to developing a therapeutic candidate.
You may also be interested in...
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.